Exagen Inc (XGN)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses

Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company continued expanding...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Exagen Inc. Reports First Quarter 2026 Results

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...